Things You Should Know

What is human growth hormone in aging?

Human growth hormone (GH) is a pituitary hormone that helps regulate growth, tissue repair, fuel use, and body composition across the life course. Much of its action is mediated through insulin-like growth factor 1 (IGF-1), a signaling hormone produced mainly in the liver and also within other tissues. In aging, the key issue is not just that GH declines, but that its actions become harder to interpret because they may support some functions while also carrying trade-offs.

This matters for longevity because longer life is not the same as stronger growth signaling. Human studies and clinical reviews suggest that normal age-related decline in GH, sometimes called the somatopause, is not automatically a disease state. In contrast, adult growth hormone deficiency (AGHD) is a specific medical disorder linked to pituitary pathology and abnormal stimulation testing. That distinction is important.

The scientific literature shows mixed patterns. Human evidence links diagnosed deficiency with poorer body composition and, in some cohorts, higher mortality. Yet animal studies often show that lifelong reduction of GH signaling can extend lifespan. These findings do not mean that adding GH to healthy older adults will extend life. They instead suggest that GH is best understood as a context-dependent regulator of maintenance, metabolism, and aging biology.

Why is GH not a simple longevity hormone?

Growth hormone (GH) is not a simple longevity hormone because it appears to support repair and function in some tissues while also being associated with processes that may raise long-term risk when signaling is excessive. Its downstream mediator, insulin-like growth factor 1 (IGF-1), can promote cell growth, protein synthesis, and aspects of brain, vascular, and muscle function. At the same time, higher GH and IGF-1 activity has been linked in parts of the literature to insulin resistance and some cancers.

Human evidence does not support a broad anti-aging benefit from GH use in otherwise healthy older adults. Reviews of clinical studies describe modest changes in lean body mass and fat mass, but these do not consistently translate into better strength, endurance, or function. Adverse effects reported in human trials include edema, joint pain, carpal tunnel symptoms, and hyperglycemia.

Preclinical evidence is also complex. Some mouse models with lifelong GH deficiency or growth hormone receptor deficiency (GHRD) live longer, while animals with very high GH levels often live shorter lives. However, those models involve developmental changes that may not apply to adults starting treatment late in life. For longevity, the available evidence favors nuance over simple replacement logic.

Which key terms help explain GH biology?

Several terms make human growth hormone (GH) easier to understand. Growth hormone receptor (GHR) is the cell-surface receptor that GH binds to in order to start signaling. After binding, pathways such as Janus kinase 2 (JAK2) and signal transducer and activator of transcription (STAT) proteins help carry the message inside the cell. These pathways influence growth, fuel use, and tissue responses.

Insulin-like growth factor 1 (IGF-1) is the main downstream hormone linked to many GH effects. Endocrine IGF-1 refers to IGF-1 circulating in blood, largely from the liver. Paracrine or local IGF-1 refers to IGF-1 made within tissues, where it may act near its site of production. This distinction matters because aging effects may differ by tissue.

Other terms also matter. Somatopause refers to the age-related decline in GH secretion. Pulsatile secretion means GH is released in bursts rather than at a steady level. Growth hormone receptor deficiency (GHRD) means the body produces GH but cannot respond normally because the receptor is impaired. These terms help explain why low GH, high GH, and GH resistance can lead to very different aging and longevity outcomes.

Who is most affected by GH-related aging issues?

The people most affected are not all older adults equally. Research suggests the main distinction is between normal aging and true adult growth hormone deficiency (AGHD). AGHD usually arises from pituitary or hypothalamic disease, trauma, or prior treatment affecting these areas. In that setting, human studies report changes in body composition, reduced muscle performance, and broader health effects that differ from ordinary aging.

Healthy older adults are a separate group. In randomized human studies, growth hormone (GH) administration in aging adults without diagnosed deficiency has shown changes in lean body mass and fat mass, but benefits for strength or physical performance have been inconsistent. Reported harms have included fluid retention, arthralgia, carpal tunnel symptoms, and elevated glucose. That makes the risk-benefit profile different from replacement in confirmed deficiency.

Another informative group includes people with growth hormone receptor deficiency (GHRD). Observational human evidence suggests they may have lower rates of cancer and diabetes, but they do not clearly live longer overall. The study population was specific, and non-aging causes of death may have influenced the lifespan findings. This is a good example of why disease burden, lifespan, and healthspan should not be treated as interchangeable outcomes.

When is GH knowledge most relevant to longevity?

Growth hormone (GH) knowledge becomes most relevant when people interpret age-related changes as a hormone problem, or when claims are made that hormone restoration will slow aging. It is also important in settings involving pituitary disease, unexplained changes in body composition, metabolic stress, and research on lifespan biology.

From a longevity perspective, timing appears to matter. Preclinical studies suggest lifelong or early-life reduction in GH signaling can shape metabolism, inflammation, stress resistance, and lifespan in ways that differ from changes beginning in adulthood. For example, animal studies indicate that early developmental exposure to GH may influence hypothalamic circuits and inflammatory tone later in life. That does not establish a similar intervention effect in humans, but it shows why life stage matters.

This topic is also relevant when discussing trade-offs between healthspan and lifespan. Human and animal studies together suggest GH may support cognition, vascular function, and muscle maintenance under some conditions, yet higher signaling may also increase insulin resistance or cancer-related concerns. In practical terms, GH is most relevant to longevity when the goal is careful interpretation of competing outcomes, not the assumption that more anabolic signaling means slower aging.

Tell Me More

How does GH interact with metabolism, stress, and exercise in aging?

Growth hormone (GH) does more than affect body size or lean mass. Available evidence suggests it also interacts with hunger, glucose control, stress responses, and exercise adaptation. In vivo animal studies show that growth hormone receptor (GHR) signaling in the hypothalamus helps regulate responses to fasting, low blood sugar, and energy demand. These findings may matter for longevity because resilience to metabolic stress can support present function, yet the same pathway may also increase insulin resistance when signaling is excessive.

The evidence is not equally strong across outcomes. Mechanistic and in vivo animal studies describe effects on neuropeptide Y (NPY), agouti-related protein (AgRP), thermogenesis, and recovery from hypoglycemia. Human evidence is narrower and supports caution: clinical studies and reviews report that GH can increase lipolysis and hepatic glucose production, but may also worsen glucose tolerance in older adults. That trade-off helps explain why a pathway that supports short-term adaptation does not automatically support longer life.

Do brain findings mean GH can protect cognition and extend lifespan?

Not necessarily. Scientific research suggests that GH has meaningful actions in the brain, including effects on memory, mood, and neural plasticity, but most of this evidence comes from in vivo animal studies. In aged rodents, growth hormone-releasing hormone (GHRH) or insulin-like growth factor 1 (IGF-1) has been associated with better spatial memory and greater microvascular density. Separate animal work also suggests GH signaling can influence fear memory, neuroinflammation, and response to low oxygen.

For longevity, the common assumption is that better brain repair or cognition may help preserve healthspan. That is a reasonable hypothesis, but it is still a hypothesis in normally aging humans. The current evidence base does not show that giving GH to healthy older adults extends life or prevents neurodegenerative disease. It instead supports a more limited conclusion: GH-related pathways may help maintain some brain functions, while excessive signaling may also impair cognition or increase inflammatory stress in animal models.

Why do low-GH models look long-lived if GH deficiency can be harmful?

This apparent contradiction reflects timing, cause, and study design. In vivo animal studies show that lifelong reduction in GH signaling, as seen in Ames dwarf, Snell dwarf, or growth hormone receptor knockout (GHRKO) models, is associated with longer lifespan, lower cancer burden, and lower diabetes incidence. Some mechanistic and observational human evidence also links growth hormone receptor deficiency (GHRD) with less cancer and diabetes. However, that does not prove that lowering GH in adulthood will extend life.

By contrast, adult growth hormone deficiency (AGHD) is a clinical disorder, usually caused by pituitary disease, and cohort studies associate untreated AGHD with higher mortality and worse health outcomes. These are different states. One reflects lifelong biology; the other reflects acquired disease. A further limitation is confounding: in one observational human GHRD cohort, reduced cancer and diabetes did not clearly translate into longer life because many deaths came from accidents, alcohol toxicity, seizures, or liver disease. Longevity depends on more than one pathway.

What misconceptions about GH and anti-aging need correction?

A frequent misconception is that restoring GH to more youthful levels will broadly restore youthful function. Human clinical studies do not support that claim in normally aging adults. Trials and reviews report modest changes in lean mass or fat mass, but little or no consistent improvement in strength, function, or aerobic capacity. Reported harms in human studies include edema, arthralgia, carpal tunnel-like symptoms, and impaired glucose control. In these trials, harms were generally assessed as adverse events during treatment, while benefits were usually measured through body composition, physical performance, or metabolic outcomes over months to years.

A second misconception is that any low GH state is inherently pro-longevity. The literature shows a more conditional picture. Reduced GH signaling across the lifespan may lower some age-related diseases in specific animal models and rare human populations, but diagnosed adult growth hormone deficiency (AGHD) is not the same as healthy aging. For longevity, the more defensible message is balance: both deficiency and excess may carry costs, and anti-aging benefit from GH treatment remains unproven in healthy older adults.

Level Up

Why does timing of GH signaling matter so much?

A major idea in the scientific literature is that growth hormone (GH) does not act the same way at every life stage. In vivo animal studies show that lifelong disruption of growth hormone receptor (GHR) signaling, as seen in Ames dwarf, Snell dwarf, and growth hormone receptor knockout (GHRKO) mice, is associated with longer lifespan, lower cancer burden, and lower diabetes incidence. Yet similar longevity effects are not reliably seen when growth hormone and insulin-like growth factor 1 (IGF-1) changes begin later, or when the reduction is more modest. In one line of mouse evidence, insulin-like growth factor 1 (IGF-1) measured early in adulthood predicted lifespan better than values measured later, which implies that developmental programming may matter more than late-life hormone levels alone.

Mechanistically, this may reflect how GH helps shape tissues while they are still developing. In vivo animal work suggests that early GH exposure can alter long-term stress resistance, kidney disease risk, and hypothalamic structure. Short peripubertal GH exposure in Ames dwarf mice reduced their longevity advantage, which supports the idea that transient early signaling can leave durable biological marks. For longevity, the implication is careful and limited: a pathway that extends life when altered from conception in mice does not automatically become a late-life anti-aging target in humans. Human evidence remains mixed and does not establish that changing GH later in life increases lifespan.

What makes GH effects so tissue-specific in aging?

Growth hormone (GH) biology is layered because it works through both endocrine and local signals. Endocrine insulin-like growth factor 1 (IGF-1) mainly refers to circulating IGF-1, much of it produced by the liver. Paracrine insulin-like growth factor 1 (IGF-1) refers to IGF-1 made within tissues, where it acts near its source. This helps explain why the same hormone axis may support one organ yet add risk in another. Reviews of human and animal evidence suggest GH and IGF-1 may help preserve muscle, vascular function, and aspects of brain aging, while also being associated with insulin resistance, kidney stress, and cancer biology when exposure is excessive or prolonged.

In vivo animal studies support this distinction. Liver-specific growth hormone receptor knockout (LiGHRKO) mice had reduced circulating insulin-like growth factor 1 (IGF-1), but they did not show the same lifespan extension or hypothalamic changes seen in whole-body growth hormone receptor knockout (GHRKO) mice. That finding suggests low blood IGF-1 alone may not explain the longevity phenotype. Local signaling inside the brain, muscle, vessels, and tumors may be just as important. For longevity, this means GH cannot be judged by one blood value alone. A given level may relate to repair in one tissue and proliferation in another, which helps explain why human mortality patterns often appear U-shaped rather than simply better at higher or lower levels.

How do stress-resistance pathways link GH to longevity?

One advanced theme is that GH-related longevity may depend less on growth itself and more on how cells handle damage. In vivo human evidence from people with growth hormone receptor deficiency (GHRD) shows reduced pro-growth signaling, lower rates of cancer and diabetes, and changes consistent with greater insulin sensitivity. Mechanistic interpretations in the scientific literature point to lower activity in pathways such as target of rapamycin (TOR), protein kinase A (PKA), and RAS, with relative activation of Forkhead box O (FOXO) stress-response programs. These pathways influence DNA repair, antioxidant defense, apoptosis, and metabolic restraint, which are all relevant to longevity.

The evidence still needs careful framing. Human growth hormone receptor deficiency (GHRD) data are observational, not randomized, and lifespan itself was not clearly extended in that cohort. Competing causes of death may have diluted any survival signal. In vivo animal evidence is stronger for lifespan extension, but species differences limit direct transfer to humans. A related mechanistic clue comes from mitochondrial biology: in mice and humans, the mitochondrial-derived peptide humanin declines with age, and its levels appear inversely related to growth hormone and insulin-like growth factor 1 (IGF-1) activity. That does not prove causation, but it supports a broader model in which lower GH signaling may shift cells toward maintenance and stress defense, which could favor healthspan under some conditions.

Where might GH longevity research go next?

The next phase will likely move away from asking whether more or less growth hormone (GH) is good in general. Research increasingly points toward stage-specific, tissue-specific, and pathway-specific questions. For example, in vivo animal studies suggest that hypothalamic inflammation may be one link between GH signaling and lifespan. Long-lived GH-deficient mice show lower glial activation and lower tumor necrosis factor alpha (TNF-α) in the hypothalamus, while liver-specific growth hormone receptor knockout (LiGHRKO) mice do not reproduce the same pattern. This suggests that direct GH action in the brain, rather than liver-derived insulin-like growth factor 1 (IGF-1) alone, may shape aging trajectories.

Another area is selective pathway targeting rather than broad hormone replacement. In vitro evidence shows that peptide antagonists can block human growth hormone receptor (hGHR) signaling, including signal transducer and activator of transcription 5 (STAT5) phosphorylation, but this is still early and not a longevity therapy. Human genetics may also guide the field, since variants in insulin-like growth factor 1 receptor (IGF-1R) and Forkhead box O3 (FOXO3) are linked with longevity in some populations. Over the next decade, the strongest progress may come from separating mechanisms that preserve repair capacity from those that raise cancer or metabolic risk. For longevity, that is a more realistic aim than treating GH as a simple anti-aging hormone.

Pros and Cons

Pros

• Lean mass may increase
  ‍In vivo human trials in healthy adults aged about 65–88 found GH was associated with modest lean mass gains and lower fat mass over 26 weeks. This may support body composition, but direct longevity benefit remains unproven.

• Fat mass may decrease
  ‍Randomized human studies reported reduced total and truncal fat with GH, and one low-dose obesity trial found weight loss was largely from body fat while lean mass was preserved. The relevance to long-term healthy aging is uncertain.

• Some aerobic gain in men
  ‍In vivo human RCTs suggest GH, especially with testosterone, was associated with modest VO2 max improvement in older men. Functional gains were limited, and similar benefits were not clearly shown in women.

• Benefit in true AGHD
  ‍In adults with diagnosed GH deficiency, clinical studies associate GH replacement with improved body composition and no clear rise in overall mortality over about 60 months. This applies to AGHD, not routine aging.

• HDL may improve at low dose
  ‍A low-dose in vivo human obesity study reported about a 19% rise in HDL cholesterol with normalized IGF-1 and no measured drop in insulin sensitivity. This was a specific population, not a general anti-aging result.

Cons

• Frequent fluid-related harms
  ‍In older adults, in vivo human RCTs found edema in about 30–39%, arthralgias in about 41–46%, and carpal tunnel symptoms in about 24–38% of GH-treated groups. These effects were much lower with placebo.

• Glucose control may worsen
  ‍Human trials reported more glucose intolerance or diabetes in GH-treated older men, and a 26-week placebo-controlled study found impaired hepatic insulin sensitivity. This trade-off may work against metabolic longevity.

• Function often does not improve
  ‍Across human trials and reviews, better body composition did not reliably translate into stronger muscles, better daily function, or better metabolism. In many studies, strength gains were absent or only marginal.

• Benefits may fade
  ‍Clinical follow-up in adults with GH deficiency found modest body-composition benefits, such as about a 5% lean mass rise, often disappeared by 24 months. About 38% dropped out due to lack of subjective improvement.

• Cancer risk remains a concern
  ‍Human observational evidence links higher IGF-1 exposure with some cancers, and reviews raise concern about long-term GH use. A clear causal risk estimate in healthy older adults is still not established, but uncertainty is material.

Considerations

• Aging is not AGHD
  ‍The evidence base separates normal somatopause from adult GH deficiency caused by pituitary disease. Findings from replacement therapy in AGHD should not be generalized to otherwise healthy older adults.

• Human and animal data differ
  ‍Animal studies often show longer lifespan with lifelong low GH signaling, while human deficiency from pituitary disease can be harmful. Timing, tissue effects, and developmental biology likely shape these different outcomes.

• Dose and duration matter
  ‍Some reports suggest lower doses may reduce short-term adverse effects, but long-term efficacy and safety remain unclear. Trials in healthy older adults were often short, commonly around 26 weeks, with limited power.

• Effects are population-specific
  ‍Most positive human findings came from defined groups, such as diagnosed AGHD, obesity, or older men given GH with sex steroids. These niche settings limit broad claims about longevity in the general population.

• Access and oversight issues
  ‍Scientific and legal reviews note that much anti-aging GH use occurs outside approved indications and often out of pocket. This can reduce monitoring quality and complicate balanced assessment of harms over time.

Actionable Intelligence

Innovative Tips

• Sleep Pulse Mapping
  ‍Human studies track sleep 2–4 weeks; GH pulses may align. Experimental, not causal.
  ‍
• Post-Lift IGF Window
  ‍Animal and mechanistic studies examine 24–48 h after lifting; local IGF signals may shift.
  ‍
• Fasting Stress Check
  ‍Animal studies assess 12–16 h fast states; GH responses may reflect metabolic strain.
  ‍
• Early-Life Lens
  ‍Animal studies suggest timing matters; lifelong GH shifts differ from late-life exposure.
  ‍
• IGF-1 Range Review
  ‍Human cohort data suggest U-shaped risk; periodic IGF-1 review is exploratory.
  ‍
• Local vs Blood IGF
  ‍Mechanistic studies distinguish tissue vs blood IGF-1; one lab value may mislead.
  ‍
• Brain Claim Filter
  ‍Animal data used 28-day GH, GHRH, or IGF-1; human cognitive benefit stays early.
  ‍
• GHR Blockade Watch
  ‍In vitro and genetic studies examine GHR blockade; human longevity benefit unproven.
  ‍
• Cancer-Risk Context
  ‍Human and animal studies link high IGF states with risk; trade-offs need context.
  ‍
• Deficiency Is Different
  ‍Human clinical data separate AGHD from aging; similar hormones, distinct evidence base.

Convergent and Divergent Viewpoints

Convergents

• Normal aging is not the same as adult GH deficiency
  ‍Clinical consensus: somatopause is not AGHD. Human evidence applies replacement mainly to pituitary disease with failed stimulation testing, not routine aging. Longevity relevance: avoid treating age alone as deficiency. Evidence: human clinical guidance/commentary.

• GH is not an established anti-aging or longevity therapy
  ‍Across human trials, reviews, and policy statements, GH has not shown a proven lifespan or broad healthspan benefit in healthy older adults. Consensus is strong and replicated. Evidence: human RCTs, systematic reviews, clinical guidance.

• Body composition changes do not reliably become functional gains
  ‍Human RCTs in adults about 65–88 years found modest lean-mass gain and fat-mass loss, but strength, daily function, and metabolism often changed little or inconsistently. Longevity value remains uncertain. Evidence: in vivo human RCTs.

• Adverse effects are frequent enough to shape risk-benefit judgment
  ‍Human trials consistently report edema, arthralgia, carpal tunnel symptoms, and hyperglycemia or diabetes signals. In one 26-week RCT, edema was about 30–39% and carpal tunnel about 24–38% with GH. Evidence: in vivo human RCTs.

• Glucose handling commonly worsens with GH exposure
  ‍Available human evidence indicates GH may impair hepatic insulin sensitivity and raise glucose-related risk in older adults, even when body composition improves. This trade-off weighs against longevity use. Evidence: in vivo human RCTs and clinical reviews.

• Long-term safety in healthy older adults remains unestablished
  ‍Experts broadly agree that months-long trials cannot settle multi-year safety, especially for cancer risk and diabetes risk. The evidence base is short and incomplete for healthy aging populations. Evidence: human trials plus clinical reviews/commentary.

• Higher IGF-1 signaling raises meaningful cancer concern
  ‍Consensus is cautious, not absolute: IGF-1 is growth-promoting, and human observational data plus mechanistic evidence raise concern about cancer risk with prolonged GH/IGF-1 elevation. Longevity trade-off is material. Evidence: human observational and mechanistic studies.

• Benefits in confirmed AGHD should not be generalized to healthy aging
  ‍Researchers agree GH replacement may help some adults with proven AGHD, but that evidence does not justify use in otherwise healthy older adults. Population boundaries are a core point of agreement. Evidence: human clinical studies and guidance.

• Animal longevity findings argue against simple 'more GH = longer life' logic
  ‍Preclinical consensus is clear: rodents with GH excess often have shorter lifespan, while several lifelong low-GH models live longer. This does not prove a human treatment effect, but it undermines anti-aging marketing claims. Evidence: in vivo animal studies.

• Use outside defined medical indications is viewed as poor scientific practice
  ‍Scientific and regulatory sources consistently hold that GH use for anti-aging in normal adults lacks adequate evidence and falls outside accepted indications. This reflects strong institutional consensus. Evidence: clinical guidance, policy, human evidence reviews.

Divergent

• Does low GH signaling in humans improve longevity, or only disease patterns?
  ‍Some researchers say rare low-GH or GH-resistance states suggest healthier aging; others say human lifespan benefit is unproven because cohorts are observational and affected by competing causes of death. Evidence: human observational studies; debate remains substantial.

• How much should body-composition improvement matter for longevity?
  ‍Some say modest lean-mass gain and fat loss may support later-life resilience; others say these changes matter little without durable gains in strength, mobility, or survival. The divide is mainly about interpretation, not the measurements. Evidence: in vivo human RCTs.

• Can lower GH doses reduce harm enough to change the equation?
  ‍Some researchers argue lower-dose regimens may lessen short-term side effects; others note efficacy and multi-year safety at such doses remain unknown, especially in older adults. The dispute persists because trials are short and small. Evidence: human trials/commentary.

• Are certain subgroups more justifiable research targets than healthy elders broadly?
  ‍Some say frail, sarcopenic, or hormonally low older adults may merit study; others argue current evidence is too limited and subgroup signals are not yet strong enough for broader inference. Evidence: small human trials and clinical interpretation.

• Should cognitive or vascular findings influence aging use of GH?
  ‍Some researchers point to brain and vascular mechanisms from animal work as a reason for continued interest; others stress that human intervention evidence is sparse and should not guide longevity use. Evidence: in vivo animal studies versus limited human data.

• Is cancer concern a likely long-term outcome or mainly a theoretical caution?
  ‍Some say the IGF-1–cancer link makes prolonged GH exposure a serious probable longevity cost; others say direct causal estimates in healthy treated elders are still lacking. Debate reflects limited long-term human trial data. Evidence: observational human and mechanistic studies.

• Does timing explain most of the paradox in GH and aging?
  ‍Some researchers argue lifespan effects depend mainly on lifelong or early-life GH exposure; others think adult tissue-specific signaling may still be modifiable later. The disagreement is mechanistic and affects translation to interventions. Evidence: animal and mechanistic studies.

• Should IGF-1 be viewed through a U-shaped longevity model?
  ‍Some say both low and high IGF-1 may carry risk, implying a U-shaped mortality pattern; others argue human data are too heterogeneous for a stable range concept across populations. Evidence: observational human studies with mixed interpretation.

Longevity Index

45/100

Definition

• Human growth hormone (GH)
  ‍A pituitary hormone that helps regulate growth, tissue repair, fuel use, and body composition across the life course.

• Pituitary hormone
  ‍A hormone produced by the pituitary gland, an endocrine gland that helps control multiple hormone systems in the body.

• Insulin-like growth factor 1 (IGF-1)
  ‍The main downstream hormone linked to many GH effects. It is produced mainly in the liver and also within other tissues.

• Somatopause
  ‍The age-related decline in GH secretion.

• Adult growth hormone deficiency (AGHD)
  ‍A specific medical disorder, usually caused by pituitary or hypothalamic disease, trauma, or prior treatment affecting these areas, and defined by abnormal stimulation testing. It is distinct from normal aging.

• Pituitary pathology
  ‍Disease or damage affecting the pituitary gland.

• Stimulation testing
  ‍A formal diagnostic test used to evaluate whether the body can appropriately release growth hormone under stimulated conditions.

• Growth hormone receptor (GHR)
  ‍The cell-surface receptor that GH binds to in order to start signaling.

• Growth hormone receptor deficiency (GHRD)
  ‍A condition in which the body produces GH but cannot respond normally because the receptor is impaired.

• Growth hormone receptor knockout (GHRKO)
  ‍An animal model in which the growth hormone receptor is genetically disabled, leading to reduced GH signaling.

• Growth hormone-releasing hormone (GHRH)
  ‍A hormone that stimulates the release of growth hormone.

• Endocrine IGF-1
  ‍IGF-1 circulating in blood, much of it produced by the liver.

• Paracrine or local IGF-1
  ‍IGF-1 made within tissues, where it acts near its site of production rather than mainly through the bloodstream.

• Pulsatile secretion
  ‍Hormone release in bursts rather than at a steady level.

• Janus kinase 2 (JAK2)
  ‍An intracellular signaling pathway component activated after GH binds its receptor, helping carry the signal inside the cell.

• Signal transducer and activator of transcription (STAT) proteins
  ‍A family of signaling proteins activated downstream of GH receptor signaling that help regulate how cells respond to the hormone.

• Signal transducer and activator of transcription 5 (STAT5) phosphorylation
  ‍A molecular activation step in which STAT5 is chemically modified to transmit GH receptor signals inside the cell.

• Hypothalamus
  ‍A brain region involved in regulating hormone release, hunger, energy balance, and stress responses.

• Hypoglycemia
  ‍Low blood sugar.

• Lipolysis
  ‍The breakdown of stored fat.

• Hepatic glucose production
  ‍The production of glucose by the liver.

• Glucose tolerance
  ‍How well the body manages blood sugar after glucose exposure.

• Insulin resistance
  ‍A state in which the body's cells respond less effectively to insulin, making blood sugar control worse.

• Hepatic insulin sensitivity
  ‍How responsive the liver is to insulin's signal to regulate glucose production.

• Hyperglycemia
  ‍High blood sugar.

• Edema
  ‍Fluid retention that causes swelling.

• Arthralgia
  ‍Joint pain.

• Carpal tunnel syndrome
  ‍A nerve compression condition at the wrist that can cause numbness, tingling, pain, or weakness in the hand.

• Lean body mass

Body mass made up largely of muscle and other non-fat tissues.

• Fat mass
  ‍The portion of body weight made up of body fat.

• Body composition
  ‍The relative amounts of fat mass and lean mass in the body.

• Aerobic capacity
  ‍The body's ability to use oxygen during sustained physical activity.

• VO2 max
  ‍A measure of maximal oxygen use during exercise, often used as an index of aerobic fitness.

• Healthspan
  ‍The period of life spent in relatively good health and functional ability.

• Lifespan
  ‍The total length of life.

• Anabolic signaling
  ‍Biological signaling that promotes growth, protein building, and tissue expansion.

• Neural plasticity
  ‍The brain's ability to adapt structurally or functionally in response to experience or injury.

• Neuroinflammation
  ‍Inflammation within the nervous system or brain.

• Microvascular density
  ‍The amount or concentration of very small blood vessels within a tissue.

• In vivo
  ‍Research performed in a living organism, such as a human or animal.

• In vitro
  ‍Research performed outside a living organism, such as in cells or tissues studied in a lab dish.

• Randomized controlled trial (RCT)
  ‍A study design in which participants are randomly assigned to treatment or control groups to test effects more reliably.

• Observational evidence
  ‍Evidence from studies that observe outcomes without assigning treatments experimentally.

• Cohort study
  ‍A study that follows a group of people over time to examine associations between exposures and outcomes.

• Confounding
  ‍A source of distortion in research where another factor influences both the exposure and the outcome, making interpretation harder.

• Developmental programming
  ‍The idea that early-life biological exposures can create lasting effects on later health and aging.

• Peripubertal
  ‍Occurring around the time of puberty.

• Ames dwarf
  ‍A long-lived mouse model with severe deficiencies in growth-related hormonal signaling.

• Snell dwarf
  ‍A long-lived mouse model with disrupted pituitary hormone production, including growth-related pathways.

• Liver-specific growth hormone receptor knockout (LiGHRKO)
  ‍An animal model in which the growth hormone receptor is disabled specifically in the liver.

• U-shaped association
  ‍A pattern in which both low and high values are associated with greater risk, while middle ranges may be more favorable.

• Target of rapamycin (TOR)
  ‍A nutrient- and growth-sensing pathway involved in cell growth, metabolism, and aging biology.

• Protein kinase A (PKA)
  ‍A signaling enzyme involved in regulating metabolism and cellular responses to hormonal signals.

• RAS
  ‍A family of signaling proteins involved in cell growth and proliferation.

• Forkhead box O (FOXO)
  ‍A family of stress-response transcription factors involved in cellular maintenance, metabolism, and longevity-related biology.

• Forkhead box O3 (FOXO3)
  ‍A member of the FOXO family that has been linked with longevity in some human populations.

• DNA repair
  ‍The set of cellular processes that detect and correct damage to DNA.

• Antioxidant defense
  ‍Cellular systems that help neutralize damaging oxidative molecules.

• Apoptosis
  ‍Programmed cell death, a controlled process cells use to remove damaged or unnecessary cells.

• Mitochondrial-derived peptide humanin
  ‍A small peptide linked to mitochondrial biology that declines with age and appears inversely related to GH and IGF-1 activity.

• Glial activation
  ‍Activation of support cells in the brain, often as part of inflammation or injury responses.

• Tumor necrosis factor alpha (TNF-α)
  ‍An inflammatory signaling molecule involved in immune and inflammatory responses.

• Insulin-like growth factor 1 receptor (IGF-1R)
  ‍The receptor that binds IGF-1 and transmits its growth-related signals into cells.

• Peptide antagonists
  ‍Small protein-like molecules designed to block a receptor or signaling pathway rather than activate it.

• hGHR signaling
  ‍Signaling through the human growth hormone receptor.

• Neuropeptide Y (NPY)
  ‍A signaling molecule in the brain involved in appetite, energy balance, and stress responses.

• Agouti-related protein (AgRP)
  ‍A hypothalamic signaling molecule involved in regulating hunger and energy balance.

• Thermogenesis
  ‍The production of heat by the body, often as part of energy expenditure.

• HDL cholesterol
  ‍High-density lipoprotein cholesterol, often discussed as a blood lipid marker associated with lipid transport.

• Insulin-like growth factor binding protein 1
  ‍A circulating binding protein linked to IGF biology and used in some studies as a marker related to hepatic insulin sensitivity.

• Anterior pituitary
  ‍The front portion of the pituitary gland that produces several key hormones, including growth hormone.

• Supraphysiologic
  ‍Higher than the normal physiological range for the body.

• Cerebrovascular
  ‍Relating to the blood vessels of the brain.

• Sarcopenic
  ‍Relating to sarcopenia, a condition of low muscle mass and reduced muscle function, often associated with aging.

‍